| Project/Area Number |
26860107
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
KODAMA Yukinobu 長崎大学, 医歯薬学総合研究科(薬学系), 助教 (50448510)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 遺伝子デリバリー / 医薬品 / 硫酸プロタミン / コンドロイチン硫酸 / siRNA |
|---|
| Outline of Final Research Achievements |
In this study, we developed the novel gene vector using regulatory-approved medical products. We used novo-protamine sulfate (PRT), chondroitin sulfate sodium (CS), stronger neo-minophagen C (GL), and sodium hyaluronate (HA) ophthalmic solution as medical products. We successfully prepared the pDNA-PRT complexes (PRT complexes) and pDNA-PRT-CS complexes (CS complexes) by optimization of the mix ratio and preparation process. PRT complexes and CS complexes showed high gene expression. Although PRT complexes showed slight cytotoxicity, CS complexes showed no cytotoxicity. Also, the gene expression of PRT complexes was greatly reduced in the presence of FBS. The presence of FBS, however, did not greatly affect gene expression of the CS complex. CS complexes showed high gene expression in the spleen after intravenous administration.
|
